A multi-center screening trial of rasagiline in patients with amyotrophic lateral sclerosis: Possible mitochondrial biomarker target engagement

Zachary Macchi, Yunxia Wang, Dan Moore, Jonathan Katz, David Saperstein, David Walk, Ericka Simpson, Angela Genge, Tulio Bertorini, J. Americo Fernandes, Andrea Swenson, Lauren Elman, Mazen Dimachkie, Laura Herbelin, Joann Miller, Jianghua Lu, Heather Wilkins, Russell H. Swerdlow, Jeffrey Statland, Richard Barohn

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Rasagiline, a monoamine oxidase B inhibitor, slowed disease progression in the SOD1 mouse, and in a case series of patients with amyotrophic lateral sclerosis (ALS). Here we determine whether rasagiline is safe and effective in ALS compared to historical placebo controls, and whether it alters mitochondrial biomarkers. We performed a prospective open-label, multicenter screening trial of 36 ALS patients treated with 2 mg oral rasagiline daily for 12 months. Outcomes included the slope of deterioration of the revised ALS Functional Rating Scale (ALSFRS-R), adverse event monitoring, time to treatment failure, and exploratory biomarkers. Participants experienced no serious drug-related adverse events, and the most common adverse event was nausea (11.1%). Rasagiline did not improve the rate of decline in the ALSFRS-R; however, differences in symptom duration compared to historical placebo controls differentially affected ALSFRS-R slope estimates. Rasagiline changed biomarkers over 12 months, such that the mitochondrial membrane potential increased (JC-1 red/green fluorescent ratio 1.92, p = 0.0001) and apoptosis markers decreased (Bcl-2/Bax ratio 0.24, p < 0.0001). In conclusion, engagement of exploratory biomarkers and questions about comparability of baseline characteristics lead us to recommend a further placebo-controlled trial.

Original languageEnglish (US)
Pages (from-to)345-352
Number of pages8
JournalAmyotrophic Lateral Sclerosis and Frontotemporal Degeneration
Volume16
Issue number5-6
DOIs
StatePublished - Aug 27 2015

Fingerprint

Amyotrophic Lateral Sclerosis
Biomarkers
Placebos
Monoamine Oxidase Inhibitors
Mitochondrial Membrane Potential
Monoamine Oxidase
Drug-Related Side Effects and Adverse Reactions
Treatment Failure
Nausea
Multicenter Studies
Disease Progression
rasagiline
Apoptosis

Keywords

  • Biomarker
  • apoptosis
  • clinical trials
  • mitochondria
  • rasagiline

Cite this

A multi-center screening trial of rasagiline in patients with amyotrophic lateral sclerosis : Possible mitochondrial biomarker target engagement. / Macchi, Zachary; Wang, Yunxia; Moore, Dan; Katz, Jonathan; Saperstein, David; Walk, David; Simpson, Ericka; Genge, Angela; Bertorini, Tulio; Fernandes, J. Americo; Swenson, Andrea; Elman, Lauren; Dimachkie, Mazen; Herbelin, Laura; Miller, Joann; Lu, Jianghua; Wilkins, Heather; Swerdlow, Russell H.; Statland, Jeffrey; Barohn, Richard.

In: Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, Vol. 16, No. 5-6, 27.08.2015, p. 345-352.

Research output: Contribution to journalArticle

Macchi, Z, Wang, Y, Moore, D, Katz, J, Saperstein, D, Walk, D, Simpson, E, Genge, A, Bertorini, T, Fernandes, JA, Swenson, A, Elman, L, Dimachkie, M, Herbelin, L, Miller, J, Lu, J, Wilkins, H, Swerdlow, RH, Statland, J & Barohn, R 2015, 'A multi-center screening trial of rasagiline in patients with amyotrophic lateral sclerosis: Possible mitochondrial biomarker target engagement', Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, vol. 16, no. 5-6, pp. 345-352. https://doi.org/10.3109/21678421.2015.1026826
Macchi, Zachary ; Wang, Yunxia ; Moore, Dan ; Katz, Jonathan ; Saperstein, David ; Walk, David ; Simpson, Ericka ; Genge, Angela ; Bertorini, Tulio ; Fernandes, J. Americo ; Swenson, Andrea ; Elman, Lauren ; Dimachkie, Mazen ; Herbelin, Laura ; Miller, Joann ; Lu, Jianghua ; Wilkins, Heather ; Swerdlow, Russell H. ; Statland, Jeffrey ; Barohn, Richard. / A multi-center screening trial of rasagiline in patients with amyotrophic lateral sclerosis : Possible mitochondrial biomarker target engagement. In: Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration. 2015 ; Vol. 16, No. 5-6. pp. 345-352.
@article{9ac4f3f52971475c8348999396cd0ad7,
title = "A multi-center screening trial of rasagiline in patients with amyotrophic lateral sclerosis: Possible mitochondrial biomarker target engagement",
abstract = "Rasagiline, a monoamine oxidase B inhibitor, slowed disease progression in the SOD1 mouse, and in a case series of patients with amyotrophic lateral sclerosis (ALS). Here we determine whether rasagiline is safe and effective in ALS compared to historical placebo controls, and whether it alters mitochondrial biomarkers. We performed a prospective open-label, multicenter screening trial of 36 ALS patients treated with 2 mg oral rasagiline daily for 12 months. Outcomes included the slope of deterioration of the revised ALS Functional Rating Scale (ALSFRS-R), adverse event monitoring, time to treatment failure, and exploratory biomarkers. Participants experienced no serious drug-related adverse events, and the most common adverse event was nausea (11.1{\%}). Rasagiline did not improve the rate of decline in the ALSFRS-R; however, differences in symptom duration compared to historical placebo controls differentially affected ALSFRS-R slope estimates. Rasagiline changed biomarkers over 12 months, such that the mitochondrial membrane potential increased (JC-1 red/green fluorescent ratio 1.92, p = 0.0001) and apoptosis markers decreased (Bcl-2/Bax ratio 0.24, p < 0.0001). In conclusion, engagement of exploratory biomarkers and questions about comparability of baseline characteristics lead us to recommend a further placebo-controlled trial.",
keywords = "Biomarker, apoptosis, clinical trials, mitochondria, rasagiline",
author = "Zachary Macchi and Yunxia Wang and Dan Moore and Jonathan Katz and David Saperstein and David Walk and Ericka Simpson and Angela Genge and Tulio Bertorini and Fernandes, {J. Americo} and Andrea Swenson and Lauren Elman and Mazen Dimachkie and Laura Herbelin and Joann Miller and Jianghua Lu and Heather Wilkins and Swerdlow, {Russell H.} and Jeffrey Statland and Richard Barohn",
year = "2015",
month = "8",
day = "27",
doi = "10.3109/21678421.2015.1026826",
language = "English (US)",
volume = "16",
pages = "345--352",
journal = "Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration",
issn = "2167-8421",
publisher = "Informa Healthcare",
number = "5-6",

}

TY - JOUR

T1 - A multi-center screening trial of rasagiline in patients with amyotrophic lateral sclerosis

T2 - Possible mitochondrial biomarker target engagement

AU - Macchi, Zachary

AU - Wang, Yunxia

AU - Moore, Dan

AU - Katz, Jonathan

AU - Saperstein, David

AU - Walk, David

AU - Simpson, Ericka

AU - Genge, Angela

AU - Bertorini, Tulio

AU - Fernandes, J. Americo

AU - Swenson, Andrea

AU - Elman, Lauren

AU - Dimachkie, Mazen

AU - Herbelin, Laura

AU - Miller, Joann

AU - Lu, Jianghua

AU - Wilkins, Heather

AU - Swerdlow, Russell H.

AU - Statland, Jeffrey

AU - Barohn, Richard

PY - 2015/8/27

Y1 - 2015/8/27

N2 - Rasagiline, a monoamine oxidase B inhibitor, slowed disease progression in the SOD1 mouse, and in a case series of patients with amyotrophic lateral sclerosis (ALS). Here we determine whether rasagiline is safe and effective in ALS compared to historical placebo controls, and whether it alters mitochondrial biomarkers. We performed a prospective open-label, multicenter screening trial of 36 ALS patients treated with 2 mg oral rasagiline daily for 12 months. Outcomes included the slope of deterioration of the revised ALS Functional Rating Scale (ALSFRS-R), adverse event monitoring, time to treatment failure, and exploratory biomarkers. Participants experienced no serious drug-related adverse events, and the most common adverse event was nausea (11.1%). Rasagiline did not improve the rate of decline in the ALSFRS-R; however, differences in symptom duration compared to historical placebo controls differentially affected ALSFRS-R slope estimates. Rasagiline changed biomarkers over 12 months, such that the mitochondrial membrane potential increased (JC-1 red/green fluorescent ratio 1.92, p = 0.0001) and apoptosis markers decreased (Bcl-2/Bax ratio 0.24, p < 0.0001). In conclusion, engagement of exploratory biomarkers and questions about comparability of baseline characteristics lead us to recommend a further placebo-controlled trial.

AB - Rasagiline, a monoamine oxidase B inhibitor, slowed disease progression in the SOD1 mouse, and in a case series of patients with amyotrophic lateral sclerosis (ALS). Here we determine whether rasagiline is safe and effective in ALS compared to historical placebo controls, and whether it alters mitochondrial biomarkers. We performed a prospective open-label, multicenter screening trial of 36 ALS patients treated with 2 mg oral rasagiline daily for 12 months. Outcomes included the slope of deterioration of the revised ALS Functional Rating Scale (ALSFRS-R), adverse event monitoring, time to treatment failure, and exploratory biomarkers. Participants experienced no serious drug-related adverse events, and the most common adverse event was nausea (11.1%). Rasagiline did not improve the rate of decline in the ALSFRS-R; however, differences in symptom duration compared to historical placebo controls differentially affected ALSFRS-R slope estimates. Rasagiline changed biomarkers over 12 months, such that the mitochondrial membrane potential increased (JC-1 red/green fluorescent ratio 1.92, p = 0.0001) and apoptosis markers decreased (Bcl-2/Bax ratio 0.24, p < 0.0001). In conclusion, engagement of exploratory biomarkers and questions about comparability of baseline characteristics lead us to recommend a further placebo-controlled trial.

KW - Biomarker

KW - apoptosis

KW - clinical trials

KW - mitochondria

KW - rasagiline

UR - http://www.scopus.com/inward/record.url?scp=84945116255&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84945116255&partnerID=8YFLogxK

U2 - 10.3109/21678421.2015.1026826

DO - 10.3109/21678421.2015.1026826

M3 - Article

C2 - 25832828

AN - SCOPUS:84945116255

VL - 16

SP - 345

EP - 352

JO - Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration

JF - Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration

SN - 2167-8421

IS - 5-6

ER -